COMPARATIVE STUDY OF STANDARD COAGULATION PROFILE IN NON-DIALYZED AND POST-DIALYZED    PATIENTS SUFFERING FROM CHRONIC KIDNEY DISEASE. by Mandi, Shakti Pada et al.
Mandi et al                                         Journal of Drug Delivery & Therapeutics. 2016; 6(3):78-83 78 
© 2011-16, JDDT. All Rights Reserved                                      ISSN: 2250-1177                                  CODEN (USA): JDDTAO 
Available online on 15.05.2016 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
An International Peer Reviewed Journal 
Open access to Pharmaceutical and Medical research 
© 2016, publisher and licensee JDDT, This is an Open Access article which permits unrestricted noncommercial use, provided the 
original work is properly cited 
 
RESEARCH ARTICLE 
 
COMPARATIVE STUDY OF STANDARD COAGULATION PROFILE IN NON-
DIALYZED AND POST-DIALYZED    PATIENTS SUFFERING FROM CHRONIC 
KIDNEY DISEASE 
                         Shakti Pada Mandi
1
, Kaushik Ghosh
2
, Sisir Chakraborty
3
, Mrinal Pal*
4
, Satyajit Koley
5 
1Department of Medicine, College of Medicine and Sagore Dutta Hospital, Kolkata, India 
2Department of Medicine, Malda,Medical College, Malda, WB, India. PIN- 732101 
3Department of Medicine, College of Medicine and Sagore Dutta Hospital, Kolkata, India 
4Department of Biochemistry, Burdwan Medical College and Hospital, Burdwan, India 
5Department of Biochemistry, Burdwan Medical College and Hospital, Burdwan, India 
Received 16 March 2016; Review Completed 08 April 2016; Accepted 09 April 2016, Available online 15 May 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION:  
Chronic kidney disease (CKD) is a condition 
characterized by permanent and significant loss of the 
glomeruler filtration rate (GFR)
 1
.  With reduction of the 
GFR, renal function deteriorates progressively and 
uremia develops. Uremia is characterized by very high 
blood urea and creatinine levels and accumulation of 
metabolic waste product. Irrespective of the cause, the 
eventual impact of chronic renal parenchymal disease is 
reflected in alteration of function of virtually every 
organ system in the body.  Coagulopathy is one of these 
effects. The association of altered hemostasis and 
uremia has long been recognized and is one of the 
leading causes of morbidity and mortality
2
. The 
haemostatic defect in uremia often is complex and 
multifactorial, including thrombocytopenia, platelet 
aggregation defects or dysfunction, and coagulation 
abnormalities.  With renal replacement therapy, one can 
treat uremia and improve CKD patients’ quality of life. 
It would be a great advantage to know whether 
correction of the biochemical abnormality lessens the 
risk of severe haemorrhagic complications, but this has 
yet to be confirmed. In this study, an attempt was made 
to correlate the laboratory results and to detect any 
subtle change in standard coagulation test results of the 
CKD patients before and after dialysis compared to 
those for a control group. 
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ABSTRACT 
Aims and Objectives: This comparative cross sectional study assessed whether there was any subtle change in the standard 
coagulation profile of chronic kidney disease (CKD) patients who needed no dialysis or who were dialysis candidates but 
had not yet started dialysis. Aim of this study was to find out  any correlation between  patients’ coagulation parameters and 
their degree of uremia. 
Materials and Methods:  A total 30 CKD patients were carefully selected and assigned to three groups after excluding 
patients who were predisposed to bleeding diathesis. Group A—10 CKD patients on the verge of hemodialysis (HD); Group 
B-10 CKD patients who were clinically and biochemically stable and on renal replacement therapy in the form of HD; and 
Group C-10 CKD patients who were in the early stages of standard medical treatment. A coagulation profile study was done 
for all three groups using nonparametric statistical analysis.  
Results and Discussion: Significant thrombocytopenia and prolongation of prothrombin time (PT) were present in (Group 
A), whereas no significant coagulation abnormality was noted in the other two groups. A significant correlation was found 
between uremia (creatinine clearance) and platelet count, P time, and APTT in Group B and Group C patients and with 
bleeding time in patients stable with conservative management (Group C).   
Conclusion: The study shows coagulation parameters are progressively affected with the progress of renal disease and that 
dialysis has an important impact on coagulopathy in CKD.  But the coagulation parameters showed no statistically 
significant correlation with degree of uremia.  
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MATERIALS AND METHODS: 
A total 30 patients suffering from renal failure of both 
sexes were included in this study.  All of the CKD 
patients were admitted to the medicine department at the 
Nil Ratan Sircar Medical College for the Management of 
Renal Failure.  CKD was diagnosed in accordance with 
available clinical, biochemical, and radiological 
guidelines 
(3,).
   
Patients were excluded if they were predisposed to 
bleeding diathesis such as those with Ischemic Heart 
Disease (IHD) and those on medications or with a 
known hematological and connective tissue disorder.   
Patients were categorized into two groups:  
Group A—10 CKD patients on the verge of 
hemodialysis (HD); Group B—10 CKD patients who 
were clinically and biochemically stable and on renal 
replacement therapy in the form of HD; and Group C—
10 CKD patients who were in the early stages of 
standard medical treatment 
Written informed consent was obtained from each 
patient before participation and the study was approved 
by Institutional Ethics Committee. The mean time period 
of these patients suffering from renal failure was 45.25 
±18.25 months. Patients undergoing dialysis was three 
times in a week for about 3 to 4 hours per session at 
blood flow rates of 180 to 375 ml/min using poly-
sulphone hollow-fiber filter. 
Blood collection and Analysis:  
Blood samples were collected by a qualified 
phlebotomist. A 2-mL blood sample from each patient 
was taken into a Lavender cap containing tube with 2.0 
mg/mL EDTA salt and preserved at 37˚C for platelet 
analysis. The blood sample was measured using the 
automatic quantitative hematology analyzer (XP-100, 
Transasia). The blood sample for coagulation function 
tests were taken into a blue capped tube containing 
sodium citrate (32.06 mg/mL, final concentration 3.8%) 
in a 9:1 volume ratio. The samples were analyzed using 
the ACL-TOP700 automatic blood coagulation analyzer 
(BECKMAN COULTER, U.S.A.). 
Platelet aggregation seems to correlate with bleeding 
time, but a platelet function study was not included in 
our study due to financial constraints. 
RESULTS AND ANALYSIS 
The collected data were treated using SPSS software 
(version 11.5).  The following statistics were calculated: 
Mean ± standard deviation,p value of each parameter, 
Correlation coefficient (r) comparing the degree of 
coagulopathy 
present and the degree of uremia (GFR-creatinine 
clearance), All tests were two-tailed, and the level of 
significance was P<0.05 
 
Table 1: Age and sex distribution of the 30 selected patients 
 25-30 years 31-40 years 41-45 years Total 
Total patients 8 11 11 30 
Male 7 6 4 18 
Female 1 5 7 12 
From Table 1, it can be seen that the greatest number of patients are in their fourth or fifth decade, with just 26% of the 
patients in their third decade. The youngest was 25-years-old and oldest was 45-years_old; the mean age was 37 ±6.4 
years. 
Table 2: Showing presenting features of 30 cases of chronic renal parenchymal disease 
Clinical features Male Female Total 
Bleeding 3 1 4  (13.3%) 
Pallor 13 5 18  (60.0%) 
Edema 7 6 13  (43.3%) 
Oliguria 3 5 8  (26.6%) 
Nausea and Vomiting 6 8 14  (46.0%) 
Weakness/Lethargy 11 8 19  (63.3%) 
 
Table 3: showing coagulation profile in pre & post dialysis group 
Analyte Predialysis group   
(Group A) 
Postdialysis group 
(Group B) 
Significance 
(P Value) 
Platelet count (x1000/cmm) 183±98.77 224.90±107.31 NS ( 0.21) 
Bleeding Time (seconds) 177.50±46.14 168±31.55 NS(0.68) 
P Time (seconds) 13.09±1.36 12.44±1.17 NS(0.13) 
APTT (seconds) 29.88±3.95 28.75±3.53 NS( 0.19) 
Value represented as mean ±SD, p value significant at the level of < 0.05 
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Bar Graph 1: Comparison of coagulation parameters between the predialysis group (Group A) and patients who were 
clinically stable postdialysis (Group B). 
 
Changes in coagulation parameters in Group A 
patients (n = 10) (predialysis group) 
 Level of platelet count was (mean ±SD) = (183 
±98.77) × 1000/cmm. 
 Number of patients having thrombocytopenia 
(<150×1000/cmm) 6 cases (60%), which is 
significant in this group (p 0.04). 
 Bleeding time (BT) was (mean ±SD) = (177.50 
±46.14) seconds.Prolonged bleeding time (>180 
seconds) was found in 4 cases (40%), which is not 
significant in this group (p>0.10). 
 Prothrombin time (P Time) (mean SD) was = ( 
13.09 ±1.36) seconds.Prolonged P Time (>13.5 
seconds) was found in 5 cases (50%), which is 
significant in this group (P 0.005). 
 Activated partial thromboplastin time (APTT) was 
(mean ±SD) = 29.88 ±3.95 seconds.Prolonged 
APTT (>33 seconds) found in 4 cases (40%), which 
is not statistically significant (p>0.10). 
 No statistical correlation was found between the 
uremia (creatinin clearance) and platelet count (r = - 
0.3133), Bleeding time (r = 0.1950),Prothrombin 
time (r = 0.3884) and Activated partial 
thromboplastin time (r = 0.4518). 
 GFR was (mean ±SD) = (8.15 ±1.75) ml/min. 
Changes in coagulation parameters in Group B 
patients (n=10) (Post-dialysis group) 
 Level of platelet count was (mean ±SD) = 
(224.09±107.31) × 1000/cmm. 
 Number of patient having thrombocytopenia = 3 
cases (30%), which is not significant in this group 
(P > 0.10). 
 Bleeding time was (mean ±SD) = (168 ±31.55) 
seconds.Number of patients having BT 
prolongation = 3 cases (30%), which is not 
significant in this study group. 
 Prothrombin time (mean ±SD) = (12.44 ±1.17) 
seconds.Number of patients having prolonged P 
time found in one case (10%), which is statistically 
not significant (P>0.10). 
 Activated partial thromboplastin time (APTT) was 
(mean ±SD) = (28.75 ±  3.53) seconds.Number of 
patient having prolonged APTT is found in one case 
(10%), which is not significant in this study group. 
 Significant correlation was found between uremia 
and platelet count  
(r = 0.03112),P Time (r = - 0.5938) and APTT (r= -
0.03359).where as uremia and bleeding time 
correlation yields nonsignificant (r = 0.3444).  
 GFR was (mean ±SD) = (8.15 ±1.75) ml/min in this 
group. 
Changes in coagulation parameters in Group C 
patients (n = 10) (patients stable with conservative 
management) 
 In this group, platelet count was (mean ±SD) = (211 
± 85.38) × 1000/cmm.only two patients (20%) were 
suffering from thrombocytopenia which is not 
significant(P = 0.0733). 
 Bleeding time was (mean ± SD ) i.e (174± 25.03) 
seconds.Number of patient having prolonged 
bleeding time found in 3 cases (30%), which is 
statistically insignificant (P > 0.10). 
 Prothrombin Time (P Time) was (mean ± SD) = 
(12.34 ±1.24) seconds.Number of patient having 
prolonged P Time was 2 cases (20%), which is 
again not significant in this group (P>0.10) 
 Activated partial thromboplastin time was (28 ± 
3.86) seconds and prolongation was noted 
insignificantly in two cases (P>0.10). 
  Here significant correlation found between uremia 
and Platelet count (r = 0.2952), P time (r = -0.1181), 
and APTT (r = -0.7972).But correlation between 
224.9 
183.0 
168.0 
177.5 
12.44 12.34 
28.75 29.88 
Post-dialysis Pre-dialysis 
Compare Mean Post-dialysis with Pre-dialysis 
Platelet Count 
(x1000/cmm) 
Bleeding time(sec) 
Ptime (sec) 
APTT(sec) 
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uremia and bleeding time was not significant in this 
study group (r = -0.6620). 
 GFR was estimated (23±5.98) ml/min in this group. 
Comparison of coagulation parameters between 
predialysis and post dialysis groups 
Total number of patient was in each group was 10 and 
included both sexes.  The platelet count, bleeding time, 
prothrombin time, and activated partial thromboplastin 
time were measured in each group. 
In the predialysis group, the platelet count was (183 
±98.77) x 1000/cmm. (mean ±SD). In the post dialysis 
patients, the platelet count was (224.90 ±107.31) x 
1000/cmm. (mean ±SD) ( Table 3). 
Showed mild improvement of platelet count after 
dialysis, but this value was not statistically significant 
(P>0.1). 
Bleeding time estimation was (177.50 ±46.14) seconds 
(mean ±SD) in the predialysis group; in the post dialysis 
group, it was (168 ±31.55) seconds (mean ±SD), which 
shows a small reduction in bleeding time after dialysis, 
but this value is not statistically significant (P>0.1). 
Prothrombin time was (13.09 ±1.36) seconds (mean 
±SD) and (12.44 ±1.17) seconds in predialysis patients 
and post dialysis patients, respectively. There was a 
small reduction of value in the post dialysis group. 
Alteration of P Time between these groups (P>0.10) was 
not statistically significant. 
Activated partial thromboplastin time was (29 ±3.95) 
seconds (mean ±SD) and (28.75 ±3.53) seconds (mean 
±SD) in predialysis patients and post dialysis patients, 
respectively. Reduction of APTT was observed in the 
post dialysis group, but it was not statistically significant 
(P>0.1).  
DISCUSSION: 
Increasing understanding of mechanism of progression 
of renal failure during the last decade may not yet have 
brought about any great changes in our current method 
of slowing the progression of renal failure, but our 
current methods of slowing the progression of various 
complications surely has added a scientific basis to 
some of the currently employed strategies. 
The precise cause of bleeding in uremia remains poorly 
understood and probably varies from person to person. 
Although the frequency of thrombocytopenia in patients 
with chronic renal failure is controversial, 
thrombocytopenia has been mostly implicated as an 
important cause of hemorrhagic diathesis in these 
patients
3
. 
In our study, we found that six patients (60%) of those 
waiting for haemodialysis had significant 
thrombocytopenia. In other patients, Group C (patients 
stable on conservative management) and Group B 
(patients from the post dialysis group) had few cases of 
thrombocytopenia— 2 (20%) and 3 (30%) cases, 
respectively. These results are similar to the results 
obtained by Grafter U et al. (1987), and Ezimol et al. 
(2004) showing thrombocytopenia
4, 5
. 
Steiner R.W et al. (1979) and Mezzano D et al. in their 
studies showed that bleeding time in uremia provides a 
useful test to assess clinical bleeding due to platelet 
dysfunction 
6,7
. 
In our study, bleeding time was prolonged in 4 (40%) 
cases from the predialysis group (Group A), 3 (30%) 
cases from the post dialysis group (Group B), and 3 
(30%) cases from the patients stable with conservative 
management (Group C). This result indicates bleeding 
time is prolonged in chronic renal parenchymal disease 
but is not statically significant (similar to findings by 
Shetty HG et al.) (1982)
8
.  
In our study, significant prolonged prothrombin time 
was found in the predialysis group (Group A) in 5 cases 
(50%), but only 1 (10%) case in the post dialysis group 
(GroupB) and 2 (20%) cases of the patients on 
conservative treatment (Group C) had prolonged P time.  
The results reported above are consistent with studies 
done by Rath et al. (1957)
9
 and Chenoy K et al. 
(1962)
10
. 
Activated partial thromboplastin time was found 
prolonged in some patients in our study— 4(40%) cases 
from the predialysis group, 1 (10%) case from the post 
dialysis group, and 2 (20%) cases from the patients on 
conservative management group.  These findings were 
not statistically significant. 
The above results from this study differ from those in 
the study done by Hutton RA et al. (1968)
11
, but contrast 
with the studies done by Shetty H.G. et al.
8
, which show 
prolonged APTT in uremia patients before dialysis, and 
Mohamed et al. (2008),which show a significant 
increase in APTT after haemodialysis 
12
. 
Four patients presented with bleeding symptoms (Case 
No. 3, 8, 10 and 13). Only Case No. 3, 8, 10 (from the 
predialysis group) have thrombocytopenia; their other 
coagulation parameters are within normal range. Case 
No. 13 has no abnormality in platelet count or other 
coagulation parameters. 
In various studies, haemostatic disturbance has been 
correlated with patient, severity of renal failure, and 
hematocrit—hemoglobin concentration overcomes the 
problem to some extent. 
In our study, a correlation was done between the degree 
of uremia (GFR) and the coagulation parameters of 
patients in each group. 
Our study shows:In Group A patients (predialysis 
group), no significant correlation was found between the 
degree of uremia and platelet count, bleeding time, 
prothrombin time, or activated partial thromboplastin 
time. 
In Group B patients (the post dialysis group), a 
significant correlation was found between uremia and 
the studied coagulation parameters, except bleeding 
time. 
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In Group C patients (those stable on conservative 
management), a significant correlation also was 
observed between uremia and the studied coagulation 
parameters. And a significant correlation was found 
between uremia and bleeding time in this study group 
(Group C). 
A moderately significant correlation was discernible 
between creatinine clearance (GFR) and partial 
thromboplastin time in chronic renal parenchymal 
disease, Shetty H G et al 
8
. 
In this study, the coagulation parameters of post dialysis 
group were compared with patients of the predialysis 
group to document whether the coagulation parameters 
changed. 
Our study shows mild improvement of platelet count, 
bleeding time, prothrombin time, and activated partial 
thromboplastin time in the post dialysis group, but this 
result is not statistically significant. 
A previous study by M L Butt (1998) showed mild 
improvement in platelet count after haemodialysis, but 
the value was not statistically significant 
13
. 
Mohamed et al. (2008) studied 90 patients finding no 
statistically significant increase in the number after 
haemodialysis. Knawczyk et al. (1994) observed an 
unchanged platelet count after haemodialysis
14
. In our 
study, the change of platelet count after haemodialysis is 
similar to that of the previous study. 
Previous studies show there is improvement of platelet 
function after haemodialysis and significant 
improvement of bleeding time. M L Butt et al. (1998) 
studied 33 patients with chronic renal failure
13
. Bleeding 
time corrected for 27 patients (81.8%) after 
haemodialysis, which was significant. Our result is in 
contrast to the result of this study. 
In our study there was no significant alteration of P time 
or APTT in post dialysis patients who were stable after 
haemodialysis when compared to the predialysis group. 
SUMMARY AND CONCLUSIONS 
Haemostasis disturbance is a common complication in 
chronic kidney disease. 
Both bleeding and thrombosis are present in chronic 
kidney patients. The main cause of this is the patient’s 
uremic state and their accumulation of other unidentified 
toxic materials. As a rule, the condition is at least partly 
reversible with adequate renal replacement therapy. 
In the present study, coagulation parameter investigation 
performed at varying intervals from diagnosis showed a 
disturbed coagulation pattern. A subtle change of 
platelet count, P time, APTT, and bleeding time was 
found in various study group patients.  These variables 
also correlated with uremia in some study group 
patients.After haemodialysis, their coagulation pattern 
improved to some extent.The possible causes of 
defective haemostatic in this situation are numerous; 
multiple mechanisms may be simultaneously involved. 
Additionally patients on haemodialysis receive various 
doses of heparin, which may cause changes in platelet 
count and coagulation factor abnormality.However, in 
the present study our effort was given to explaining 
subtle coagulation abnormalities and determining 
whether there were any changes with renal replacement 
therapy (haemodialysis) to prevent serious bleeding 
complications for those patients who may be planning 
surgical intervention or invasive diagnostic procedures 
in the future. 
Conclusions we have drawn from the present study are: 
(1) In the predialysis group, all of the studied 
parameters were affected more than in the group of 
patients who were stable with conservative 
management.  So the coagulation parameters are 
progressively affected as the renal disease progresses. 
(2) In the group that was studied after dialysis, all 
the coagulation factors improved to a certain extent. So 
dialysis has an important impact on coagulopathy in 
CKD. 
(3) In all of the groups studied, the coagulation 
parameters have no statistically significant correlation 
with the degree of uremia, i.e. GFR. This may be 
because each of the three patient groups was different 
and each case was not studied as the disease progressed. 
The study is a cross-sectional study comprising a small 
population of patients, so no firm conclusion can be 
drawn whether coagulopathy is related to the degree of 
chronic renal damage.  
More study is necessary with a large number of cases to 
arrive at a definite conclusion regarding coagulation 
abnormality in chronic renal parenchymal disease.  
However, the present study gives an overall idea about 
coagulopathy in CKD in our population, as depicted in 
previous literatures. 
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